

Novavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024

May 7, 2024

GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows:

Conference call details:

Date: May 10, 2024
Time: 8:30 a.m. U.S. ET
URL to register phone: <https://emportal.in/3VNP8J5>
Dial-in number: (888) 664-6383 (Domestic) or
(+1) (416) 764-8650 (International)
Webcast: ir.novavax.com/events

- *Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.*
- *Participants can also dial direct to be entered into the call by an Operator and will be prompted to request to join the Novavax, Inc. call.*
- *To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.*

Replay details:

Date: Available starting at 11:30 a.m. ET, May 10, 2024, until 11:59 p.m. U.S. ET, May 17, 2024
Dial-in number: (888) 390-0541 (Domestic) or
(+1) (416) 764-8677 (International)
Passcode: 414036#
Webcast: ir.novavax.com/events, until June 10, 2024

About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and [LinkedIn](#) for more information.

Contacts:

Investors

Erika Schultz
240-268-2022
ir@novavax.com

Media

Giovanna Chandler
202-709-5563
media@novavax.com

SOURCE Novavax, Inc.